Search bioRxiv⌕ Search

Biology subjects

Bustos, V.

Publications and source records attributed to Bustos, V..

3 recordsLinked to original sources

DNA-binding-independent mechanisms of metabolic regulation by the Drosophila FOXO transcription factor

Forkhead box-O (FOXO) transcription factors are evolutionarily conserved regulators of several biological processes, including development, stress responses, metabolism and ageing. As downstream effectors of nutrient-dependent cell signalling pathways, including insulin/IGF signalling, they integrate signals from multiple stimuli to orchestrate appropriate transcriptional responses to changes in the nutritional environment. Traditionally, FOXO-dependent responses have been attributed to target gene regulation through direct interactions with regulatory regions by DNA-binding via the conserved Forkhead (FH) domain. However, emerging evidence suggests that FOXO proteins may also influence gene expression through DNA-binding-independent mechanisms. However, differences in transcriptional outputs between DNA-binding dependent and independent FOXO functions have yet to be explored. Here, we have used genomic engineering of the endogenous Drosophila foxo locus to disrupt the DNA-binding activity of the single fly FOXO orthologue, allowing us to dissect the in vivo contributions of canonical and non-canonical dFOXO functions. We show that while DNA-binding is essential for several dFOXO-mediated phenotypes including female fecundity, lifespan, and resistance to oxidative and xenobiotic stress, other traits such as adult body size and survival during starvation remain intact. Notably, DNA-binding-deficient dFOXO flies exhibit defective lipid mobilisation under starvation, implicating a DNA-binding-independent role for dFOXO in metabolic regulation. Differential gene expression analysis during starvation in these mutants revealed key transcriptional changes in genes encoding metabolic regulators as well as regulators of transcription and chromatin structure. Together, these findings reveal distinct modes of dFOXO transcriptional regulation that depend on its direct association with DNA.

genetics↗

Rational development of a small-molecule activator of CK1γ2 that decreases C99 and beta-amyloid levels

Alzheimers disease (AD) is a debilitating neurodegenerative disorder characterized by the accumulation of beta-amyloid (A{beta}), C99, and Tau in vulnerable areas of the brain. Despite extensive research, current strategies to lower A{beta} levels have shown limited efficacy in slowing the cognitive decline associated with AD. Recent findings suggest that C99 may also play a crucial role in the pathogenesis of AD. Our laboratory has discovered that CK1{gamma}2 phosphorylates Presenilin 1 at the {gamma}-secretase complex, leading to decreased C99 and A{beta} levels. Thus, CK1{gamma}2 activation appears as a promising therapeutic target to lower both C99 and A{beta} levels. In this study, we demonstrate that CK1{gamma}2 is inhibited by intramolecular autophosphorylation and describe a high-throughput screen designed to identify inhibitors of CK1{gamma}2 autophosphorylation. We hypothesize that these inhibitors could lead to CK1{gamma}2 activation and increased PS1-Ser367 phosphorylation, ultimately reducing C99 and A{beta} levels. Using cultured cells, we investigated the impact of these compounds on C99 and A{beta} concentrations and confirmed that CK1{gamma}2 activation effectively reduces their levels. Our results provide proof of concept that CK1{gamma}2 is an attractive therapeutic target for AD. Future studies should focus on the identification of specific compounds that can inhibit CK1{gamma}2 autophosphorylation and evaluate their efficacy in preclinical models of AD. These studies will pave the way for the development of novel therapeutics for the treatment of AD.

pharmacology and toxicology↗

C99, not beta-amyloid, is associated with selective death of vulnerable neurons in Alzheimer's disease.

IntroductionThe levels and distribution of amyloid deposits in the brain does not correlate well with Alzheimers disease (AD) progression. Therefore, it is likely that Amyloid-precursor-protein proteolytic fragments other than beta-amyloid contribute to the onset of AD.\n\nMethodsWe developed a sensitive assay adapted to the detection of C99, the direct precursor of beta-amyloid. Three postmortem groups were studied: control with normal and stable cognition; subjects with moderate AD, and individuals with severe AD. The amount of C99 and beta-amyloid was quantified and correlated with the severity of AD.\n\nResultsC99 accumulates in vulnerable neurons, and its levels correlate with the degree of cognitive impairment in patients suffering from AD. In contrast, beta-amyloid levels are increased in both vulnerable and resistant brain areas.\n\nDiscussionThese results raise the possibility that C99, rather than beta-amyloid plaques, is responsible for the death of nerve cells in Alzheimers disease.

neuroscience↗